Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis

Rheumatology (United Kingdom)

Volumn 57, Issue 6, 2018, Pages 997-1001

  Rutherford, Andrew I ^a,b   Patarata, Eunice ^b,c   Subesinghe, Sujith ^a   Hyrich, Kimme L ^d,e   Galloway, James B ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c HOSPITAL CURRY CABRAL   (Portugal)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Biologic; Infection; Opportunistic; Rheumatoid; Tuberculosis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; BIOLOGICAL PRODUCT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASPERGILLOSIS; BIOLOGICAL THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DAS28; DISEASE SEVERITY; FOLLOW UP; HERPES ZOSTER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PNEUMOCYSTOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TUBERCULOSIS; AGE; AGED; CLINICAL TRIAL; COMPLICATION; FEMALE; FORECASTING; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; REGISTER; RHEUMATOLOGY; SEX FACTOR; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; FEMALE; FOLLOW-UP STUDIES; FORECASTING; HUMANS; INCIDENCE; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDIES; REGISTRIES; RHEUMATOLOGY; SEX FACTORS; UNITED KINGDOM;

EID: 85047417783     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/key023     Document Type: Article

References (14)

1. Askling J, Fored CM, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44
2. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011;50:124-31
3. Kaplan JE, Benson C, Holmes KK et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009;58:1-207, quiz CE1-4
4. Winthrop KL, Novosad SA, Baddley JW et al. Opportunistic infections and biologic therapies in immunemediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance. Ann Rheum Dis 2015;74:2107-16
5. Mercer LK, Galloway JB, Lunt M et al. Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis 2017;76:497-503
6. Dixon WG, Hyrich KL, Watson KD et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69:522-8
7. Tuberculosis Section Centre for Infectious Disease Surveillance and Control, National Infection Service. Tuberculosis in England 2016 Report. Public Health England, London, England; 2016
8. Salmon-Ceron D, Tubach F, Lortholary O et al. Drugspecific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616-23
9. Lund FE, Hollifield M, Schuer K et al. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006;176:6147-54
10. Martin-Garrido I, Carmona EM, Specks U, Limper AH. Pneumocystis pneumonia in patients treated with rituximab. Chest 2013;144:258-65
11. Jiang X, Mei X, Feng D, Wang X. Prophylaxis and treatment of Pneumocystis jiroveci Pneumonia in lymphoma patients subjected to rituximab-contained therapy: a systemic review and meta-analysis. PLoS One 2015;10:e0122171
12. Bharat A, Xie F, Baddley JW et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res 2012;64:612-5
13. Ledingham J, Wilkinson C, Deighton C. British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNFalpha treatments. Rheumatology (Oxford) 2005;44:1205-6
14. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104